Intercept Pharmaceuticals Inc (ICPT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Intercept Pharmaceuticals Inc (ICPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9799
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company owns worldwide rights to OCA except for China, Japan and Korea, where the rights were exclusively licensed to Sumitomo Dainippon Pharma Co., Ltd., (Sumitomo Dainippon) along with an option to exclusively license OCA in certain other Asian countries. The product is also under development for the treatment of various other liver diseases. Intercept’s other developmental products in pipeline include INT-767 for the treatment of fibrosis; and INT-777 for type 2 diabetes. Intercept is headquartered in New York, the US.

Intercept Pharmaceuticals Inc (ICPT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Intercept Pharma Raises US$30 Million In Series C Financing 10
Partnerships 12
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept Pharma Enters into Research Agreement with University of Perugia 13
Equity Offering 14
Intercept Pharma Prices Private Placement of Shares for USD100 Million 14
Intercept Pharma Prices Public Offering of Shares for USD150 Million 16
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 18
Intercept Pharma Raises USD202 Million in Public Offering of Shares 20
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 22
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 24
Intercept Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$86 Million 26
Debt Offering 28
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 28
Intercept Pharmaceuticals Inc – Key Competitors 30
Intercept Pharmaceuticals Inc – Key Employees 31
Intercept Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Financial Announcements 34
Oct 31, 2018: Intercept Pharmaceuticals reports third quarter 2018 financial results and provides business update 34
Aug 02, 2018: Intercept Pharmaceuticals reports second quarter 2018 financial results and provides business update 36
May 08, 2018: Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance and Provides Business Update 38
Feb 14, 2018: Intercept Pharmaceuticals Reports Net Sales Of $129.2 Million For The Year Ended December 31, 2017 40
Jul 31, 2017: Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 43
May 04, 2017: Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 45
Feb 23, 2017: Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update 47
Corporate Communications 50
Nov 27, 2017: Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intercept Pharma Raises US$30 Million In Series C Financing 10
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept Pharma Enters into Research Agreement with University of Perugia 13
Intercept Pharma Prices Private Placement of Shares for USD100 Million 14
Intercept Pharma Prices Public Offering of Shares for USD150 Million 16
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 18
Intercept Pharma Raises USD202 Million in Public Offering of Shares 20
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 22
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 24
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$86 Million 26
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 28
Intercept Pharmaceuticals Inc, Key Competitors 30
Intercept Pharmaceuticals Inc, Key Employees 31
Intercept Pharmaceuticals Inc, Other Locations 32
Intercept Pharmaceuticals Inc, Subsidiaries 32

List of Figures
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Intercept Pharmaceuticals Inc (ICPT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MKB Private Banking:企業の戦略・SWOT・財務分析
    MKB Private Banking - Strategy, SWOT and Corporate Finance Report Summary MKB Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Showa Aircraft Industry Co., Ltd.
    Showa Aircraft Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Showa Aircraft Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Pension Insurance Corporation plc:企業の戦略・SWOT・財務情報
    Pension Insurance Corporation plc - Strategy, SWOT and Corporate Finance Report Summary Pension Insurance Corporation plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Vestas Wind Systems AS (VWS)-エネルギー分野:企業M&A・提携分析
    Summary Vestas Wind Systems A/S (Vestas) is a renewable energy company that designs, manufactures, constructs, installs, and services wind turbines. The company partners with customers to monitor wind energy production and performance of the wind power plant throughout its lifetime. It offers soluti …
  • High Plains Power Inc:企業の戦略的SWOT分析
    High Plains Power Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Envision Solar International Inc (EVSI):電力:M&Aディール及び事業提携情報
    Summary Envision Solar International Inc (Envision Solar) is a provider of energy security systems. The company's products include renewably energized electric vehicle charging systems, media and branding systems, energy security systems, patented solar tracking systems, energy storage systems, elec …
  • Asahi Kasei Corp (3407)-エネルギー分野:企業M&A・提携分析
    Summary Asahi Kasei Corp (Asahi Kasei), formerly Asahi Chemical Industry Co. Ltd., manufactures, processes, and sells chemical products. It is a holding company of Asahi Kasei Group. The product portfolio of the company includes polymers, acrylonitrile, styrene, diagnostic reagents, foam insulation …
  • Altice USA, Inc. (ATUS):企業の財務・戦略的SWOT分析
    Altice USA, Inc. (ATUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • AMETEK Inc (AME):企業の財務・戦略的SWOT分析
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturer. The company manufactures electronic instruments and electromechanical devices. Its product portfolio includes medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titanium alloys a …
  • Puget Sound Energy Inc:電力:M&Aディール及び事業提携情報
    Summary Puget Sound Energy Inc (PSE), a subsidiary of Puget Energy Inc, is a utility service provider. The company offers offers services such as energy and natural gas supply, start service, power outages, natural gas safety, business services, natural gas storage and excess generation of energy. I …
  • Delong Holdings Limited:企業の戦略・SWOT・財務情報
    Delong Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Delong Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • CompuGroup Medical Deutschland AG (COP)-医療機器分野:企業M&A・提携分析
    Summary CompuGroup Medical Deutschland AG (CGM) is a provider of medical software products and healthcare services. The company's products comprise communication solutions, software assisted medicine, dentist information systems, ambulatory information systems, drug safety, patient marketing, and ot …
  • Bankers Petroleum Ltd:企業の戦略的SWOT分析
    Bankers Petroleum Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Abu Dhabi National Energy Co (TAQA):電力:M&Aディール及び事業提携情報
    Summary Abu Dhabi National Energy Company (TAQA), a subsidiary of government-owned Abu Dhabi Water and Electricity Authority, is an energy and water company. It undertakes power generation; exploration, development, production and storage of oil and gas; pipelines and gas storage; and water desalina …
  • Al Safeer Group of Companies:企業の戦略・SWOT・財務情報
    Al Safeer Group of Companies - Strategy, SWOT and Corporate Finance Report Summary Al Safeer Group of Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Abeona Therapeutics Inc (ABEO)-医療機器分野:企業M&A・提携分析
    Summary Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company focusing on the development and delivery of gene therapy and plasma-based products for severe and life-threatening rare diseases. The company’s lead programs include ABO-101 and ABO …
  • Nayara Energy Ltd:企業の戦略的SWOT分析
    Nayara Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Sibanye Gold Ltd:企業の戦略・SWOT・財務情報
    Sibanye Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Sibanye Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Tribune Media Company:戦略・SWOT・企業財務分析
    Tribune Media Company - Strategy, SWOT and Corporate Finance Report Summary Tribune Media Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Amedica Corp (AMDA):医療機器:M&Aディール及び事業提携情報
    Summary Amedica Corp (Amedica) is a biomaterial company that develops, produces and markets medical-grade silicon nitride ceramics for spinal implants and arthroplasty applications. The company offers interbody fusion devices, pedicle screw systems, facet fixation systems. It also offers non-silicon …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆